GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » Cyclically Adjusted PS Ratio

Oncolytics Biotech (Oncolytics Biotech) Cyclically Adjusted PS Ratio : (As of Apr. 27, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Oncolytics Biotech Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Oncolytics Biotech Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Oncolytics Biotech's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech Cyclically Adjusted PS Ratio Chart

Oncolytics Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oncolytics Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oncolytics Biotech's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Oncolytics Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncolytics Biotech's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's Cyclically Adjusted PS Ratio falls into.



Oncolytics Biotech Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Oncolytics Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Oncolytics Biotech's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/125.4675*125.4675
=0.000

Current CPI (Dec. 2023) = 125.4675.

Oncolytics Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.000 98.604 0.000
201406 0.000 99.473 0.000
201409 0.000 99.394 0.000
201412 0.000 98.367 0.000
201503 0.000 99.789 0.000
201506 0.000 100.500 0.000
201509 0.000 100.421 0.000
201512 0.000 99.947 0.000
201603 0.000 101.054 0.000
201606 0.000 102.002 0.000
201609 0.000 101.765 0.000
201612 0.000 101.449 0.000
201703 0.000 102.634 0.000
201706 0.000 103.029 0.000
201709 0.000 103.345 0.000
201712 0.000 103.345 0.000
201803 0.000 105.004 0.000
201806 0.000 105.557 0.000
201809 0.000 105.636 0.000
201812 0.000 105.399 0.000
201903 0.000 106.979 0.000
201906 0.000 107.690 0.000
201909 0.000 107.611 0.000
201912 0.000 107.769 0.000
202003 0.000 107.927 0.000
202006 0.000 108.401 0.000
202009 0.000 108.164 0.000
202012 0.000 108.559 0.000
202103 0.000 110.298 0.000
202106 0.000 111.720 0.000
202109 0.000 112.905 0.000
202112 0.000 113.774 0.000
202203 0.000 117.646 0.000
202206 0.000 120.806 0.000
202209 0.000 120.648 0.000
202212 0.000 120.964 0.000
202303 0.000 122.702 0.000
202306 0.000 124.203 0.000
202309 0.000 125.230 0.000
202312 0.000 125.468 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Oncolytics Biotech  (NAS:ONCY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Oncolytics Biotech Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncolytics Biotech (Oncolytics Biotech) Business Description

Traded in Other Exchanges
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.

Oncolytics Biotech (Oncolytics Biotech) Headlines

From GuruFocus